Introduction {#sec1}
============

While membrane proteins comprise a significant percentage of the human proteome,^[@ref1]^ the determination of the structures of ligands and drug candidates bound to these proteins in a membrane microenvironment is an ongoing and formidable challenge.^[@ref2]^ Furthermore, membrane-associated proteins (MAPs) interact with phospholipid bilayers in a dynamic fashion and introduce additional complexity for relevant X-ray structure determinations as crystal packing forces could disrupt or distort the MAP--ligand--membrane complex.^[@ref3]^ The large size of a MAP--ligand--membrane complex with restricted mobility also poses a challenge to solution-state NMR analysis.^[@ref3]^ Representative of MAPs, protein kinase C (PKC) isoforms^[@ref4],[@ref5]^ play a central role in cellular signal transduction through the phosphorylation of a diverse array of proteins involved in cell growth, differentiation, proliferation, and apoptosis.^[@ref6],[@ref7]^ More generally, PKC isoforms^[@ref8]−[@ref12]^ and mutated PKCs^[@ref13],[@ref14]^ have been implicated in numerous therapeutic indications including HIV/AIDS eradication, Alzheimer's disease, cancer immunotherapy, cardiovascular disease, pain, and stroke, among others. Yet nothing is known about the bound conformations of endogenous (e.g., diacylglycerols) or exogenous (e.g., phorbol esters, prostratin, bryostatins, daphnane diterpenoid orthoesters, ingenanes, aplysiatoxin, and teleocidins) PKC modulatory ligands in a membrane environment. Such information is critical for understanding how these agents function at a molecular level and more importantly how one might design superior, more accessible, and better tolerated analogues.

Bryostatin^[@ref15]−[@ref17]^ is a marine-derived PKC modulator now in clinical trials for Alzheimer's disease and HIV/AIDS eradication. Its original GMP (good manufacturing practice) supply is nearly depleted.^[@ref18]^ Efforts to design superior, better tolerated, and more synthetically accessible ligands^[@ref19]^ have progressed^[@ref20]−[@ref23]^ but rely on computer-guided ligand comparisons^[@ref24]−[@ref26]^ and models^[@ref27]−[@ref29]^ that lack experimental information on the structure(s) of the PKC-bound ligand in a membrane microenvironment. Here, we use REDOR solid-state NMR^[@ref30]−[@ref35]^ to determine the conformations of PKC modulators bound to the 51-residue PKCδ-C1b regulatory domain with phosphatidylserine (PS) multilamellar vesicles as the membrane surrogate. Using the conformationally limited phorbol diacetate (PDAc, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) as an initial test ligand, we find unanticipated partitioning of PDAc between a mobile lipid-associated state and an immobilized protein-bound state, but identify a single conformation in the bound state. In striking contrast, the bryostatin analogue, bryolog 1, adopts *multiple* bound conformations. The molecular distribution revealed by REDOR NMR is supported by molecular dynamics simulations and demonstrates a departure from prior studies which have sought out and presented only a single, lowest-energy, PKC-bound conformation. This finding represents a fundamentally new way to think about PKC ligand binding and calls attention to the importance of multistage contributions to the binding and function of membrane-bound protein--ligand complexes. The work indicates the need to consider molecular flexibility when designing and developing new ligands to modulate PKC function. For example, PDAc is rigid and is a tumor promoter, whereas the more flexible bryostatin exhibits therapeutic potential in cancer therapy. Furthermore, we present an experimental platform to address outstanding questions involving the binding of other bryologs and other MAP ligands.

![Determination of the bound conformation and accounting of PKCδ-C1b-bound PDAc. (A) Phorbol diacetate is depicted as an overlay of two energetically accessible conformers, highlighting the *in silico* calculated distance between the C12-OAc carbonyl and the internuclear average of the C13-OAc deuterons. (B) ^13^C cross-polarization magic-angle-spinning (CPMAS) spectrum of the \[^13^C,^2^H~3~\]PDAc--PKCδ-C1b--phosoholipid vesicle complex, acquired as an 8 *T*~r~ (rotor period) echo with 20,000 scans and MAS at 7143 Hz. By spin counting, there are 1.2 μmol of PDAc in the NMR sample. (C) C{D} REDOR spectra were obtained at 11 evolution times, and the REDOR dephasing is best fit to an internuclear distance of 5.1 ± 0.2 Å (reduced χ^2^ value of 1.85), corresponding to a 35 ± 4 Hz best fit for the dipolar coupling. Error bars are based on the signal-to-noise ratio of each spectrum. Approximately 140,000 scans of S~0~ and S were obtained for the \[^13^C,^2^H~3~\]PDAc complex at the early evolution times of 4.48 and 6.72 ms where the REDOR differences were small (13 days total). 60--90,000 scans were collected for later evolution times (requiring an additional 30 days of acquisition). Experimentally corrected S~0~ spectra corresponding to the ^13^C label in PDAc without contributions from natural abundance carbons were obtained by subtracting the corresponding full-echo spectrum of \[^2^H~3~\]PDAc (12 days acquisition) from the \[^13^C,^2^H~3~\]PDAc spectrum (normalized to the 172 ppm carbonyl peak intensity) for each evolution time (as shown in [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.7b00475/suppl_file/oc7b00475_si_001.pdf)). (D) C{D} REDOR spectra resulting from 160 *T*~r~ (22.40 ms) of evolution for the doubly labeled \[^13^C,^2^H~3~\]PDAc complex (left) and a control complex in which the PDAc was labeled only with ^2^H (right). 40% dephasing is observed for the PDAc carbonyl (left), and there is no dephasing for other natural abundance carbons (right). (E) ^2^H Hahn echo spectra of the \[^13^C,^2^H~3~\]PDAc--PKC--phospholipid vesicle complex. ^2^H Hahn echoes were obtained with a long (8 s, red) and a short (0.5 s, blue) recycle delay. The 0.5 s delay ^2^H spectrum is right-shifted for clarity and is the result of 100,000 scans, and the 8 s delay ^2^H spectrum is the result of 11,000 scans, both with MAS at 7143 Hz.](oc-2017-00475g_0005){#fig1}

Results and Discussion {#sec2}
======================

Experimental measurements of long-range intraligand dipolar couplings report directly on distances and, thus, the ligand structure or conformational ensemble of ligand structures in a macromolecular assembly.^[@ref32]−[@ref34]^ We introduced a design strategy involving the synthesis of bryolog 1, selectively installing ^13^C, ^19^F, and ^2^H isotopic labels across the molecule ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A) to enable the measurement of long-range intraligand distances of the membrane-associated PKCδ-C1b-bound bryolog using REDOR NMR.^[@ref36]^ The feasibility and sensitivity of the REDOR-based approach were first evaluated with a more conformationally limited PKC substrate, PDAc, designed and synthesized to report on one ^13^C--^2^H distance of approximately 5 Å. As a phorbol diester, PDAc belongs to one of the most studied classes of biologically active molecules.^[@ref37]^*In silico* analysis of PDAc revealed that the C12 and C13 acyloxy carbonyls are 5.0 ± 0.5 Å away from the α-position of their counterpart, regardless of the conformation of the C12 acetoxy group ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A). A ^13^C label was installed at the C12-OAc carbonyl position, and ^2^H was incorporated as a CD~3~ group on the C13-OAc, where the REDOR-determined distance would extend from the C12 carbonyl to the average position of the three deuterons ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). Labeled ligands were complexed with a 51-residue peptide corresponding to the mouse PKCδ-C1b domain,^[@ref38]^ allowing comparison of previous structural studies^[@ref39]−[@ref50]^ using this isoform domain, which recapitulates the ligand binding capabilities of the full-length protein.^[@ref51]^ The folding and function of PKC and its C1 domain are sensitive to its environment, and in the case of membrane-associated PKC, we have shown that the C1 domain does not fold properly for binding in water alone but only in association with a PS vesicle.^[@ref51]^ Thus, complexes were assembled in association with PS vesicles as the membrane surrogate, using a 1:1:50:50 molar ratio of ligand:PKCδ-C1b:phosphatidylserine:trehalose in Tris buffer. This peptide-phospholipid composition yielded a *K*~d~ value of 1.5 nM for the high affinity ligand phorbol 12,13-dibutyrate (PDBu), comparable to affinity observed when using a ratio of ∼4300:1 that is employed in standard radioactivity-based binding assays^[@ref52]^ (0.36--0.52 nM; see [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.7b00475/suppl_file/oc7b00475_si_001.pdf)).

The ^13^C spectrum of the peptide--ligand--phospholipid complex includes natural abundance ^13^C contributions from the PKCδ-C1b and phosphatidylserine in addition to the labeled ^13^C carbonyl contribution from the \[^13^C,^2^H~3~\]PDAc, fortunately shifted upfield of carbonyl peaks associated with the peptide and phospholipids ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). The spectrum of a comparative sample of protein complexed with \[^2^H~3~\]PDAc confirmed the \[^13^C,^2^H~3~\]PDAc ^13^C chemical shift assignment ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.7b00475/suppl_file/oc7b00475_si_001.pdf)). A full C{D} REDOR dephasing curve plotted as the percent dephasing (ΔS/S~0~) for multiple evolution times was obtained, with 42% dephasing observed after 24.64 ms of dipolar evolution ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C). No dephasing was observed for the \[^2^H~3~\]PDAc complex ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}D), confirming that the dephasing in the \[^13^C,^2^H~3~\]PDAc complex arises only from the PDAc ^13^C--^2^H dipolar coupling. The experimental REDOR curve fit a distance of 5.1 ± 0.2 Å, matching the *in silico* prediction. However, the REDOR dephasing exhibited a plateau of 42% and did not reach the maximum theoretical C{D} REDOR dephasing of 73% (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.7b00475/suppl_file/oc7b00475_si_001.pdf)), indicating that some ^13^C--^2^H dipolar couplings were not detected. REDOR experiments on \[^13^C,^2^H~3~\]zinc acetate yielded the theoretically expected maximum dephasing of 74%.^[@ref53]^

We hypothesized that the reduced plateau could be attributed to mobile PDAc that was phospholipid-associated but not peptide-bound. Anisotropic motion faster than the strength of the ∼35 Hz ^13^C--^2^H dipolar coupling would interfere with REDOR dephasing, but still allow ^13^C to be observed in the REDOR full-echo reference (S~0~) spectrum. In this way, the experimental determination of the REDOR ΔS/S~0~ plateau established a total accounting only of the rigid ligand. A ^2^H Hahn echo spectrum independently served as a reporter of PDAc motion and revealed that a significant fraction of the PDAc was mobile, with a prominent center band (red) corresponding to motional averaging of the ^2^H quadrupolar anisotropy tensor ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}E). The ^2^H Hahn echo spectrum acquired with a shorter recycle delay of 0.5 s, instead of 8 s, exhibited further diminution of the broad sideband pattern corresponding to the rigid component (with a longer *T*~1~) relative to the mobile ^2^H center band. Comparison of the integrated peak intensities of the two ^2^H Hahn echo spectra indicated that the rigid peptide-bound fraction is 55%, where the spectrum collected with the 8 s recycle delay (in red) has all PDAc contributions and the spectrum resulting from the shorter recycle delay (blue) reports only on mobile PDAc ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}E). The REDOR plateau would be 40% if 55% of the PDAc was rigid and peptide-bound (55% of the maximum theoretical dephasing of 73%), which is in close agreement with the experimentally observed plateau of 42%. Thus, based on the C{D} REDOR NMR and the independent evaluation of the amount of mobile ligand by observing ^2^H, we conclude that 55--57% of the PDAc is bound to PKC. The remaining 43--45% is mobile. The specific distance of 5.1 Å between the PDAc C12-OAc ^13^C and the C13-OAc CD~3~ indicates that PDAc adopts a conformation in which a C9-OH is hydrogen bonded to a C13-OAc when bound to PKCδ-C1b in phospholipid vesicles. This intramolecular hydrogen bond is known to be central to function,^[@ref54]^ as phorbol (C12-OH, C13-OAc) disrupts this interaction in favor of a C12-OH to C13-OAc hydrogen bond and does not achieve nanomolar binding affinity to PKC.

![Isotope-labeling strategy and representative REDOR NMR spectra of the PKCδ-C1b-bound bryolog 1. (A) Chemical structure and locations of isotopic labels in bryolog 1. (B) Molecular view of PKCδ-C1b-bound bryolog 1 in association with phospholipids. (C) C{F} REDOR spectra of \[^19^F,^13^C,^2^H~3~\]bryolog--PKCδ-C1b--phospholipid complex and \[^2^H~3~\]PDAc--PKCδ-C1b--phospholipid complex at 128 *T*~r~ (17.92 ms). The bryolog full-echo S~0~ (bottom left spectrum) contains contributions from ^13^C label in bryolog 1 and the natural abundance ^13^C from PKCδ-C1b and phospholipids. The bryolog-only S~0~ (bottom right spectrum) is obtained by subtracting the PKCδ-C1b and phospholipids natural abundance ^13^C (using the natural abundance PDAc full-echo S~0~, top left spectrum) from the bryolog full-echo S~0~.](oc-2017-00475g_0001){#fig2}

REDOR NMR and molecular dynamics were next employed to define the conformation of bryolog 1 bound to PKCδ-C1b in phospholipid vesicles. The positioning of labels in this analogue was guided by computational analysis and intended to enable differentiation of a bound conformer from a range of conformational possibilities. Bryolog 1 exhibited a binding affinity of approximately 1 nM to PKCδ, statistically indistinguishable from bryostatin itself.^[@ref36]^ The three possible heteronuclear distance measurements were made between ^13^C, ^2^H, and ^19^F using REDOR NMR. In each case, the analytical REDOR results provided unambiguous evidence of distance distributions^[@ref55]^ ([Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.7b00475/suppl_file/oc7b00475_si_001.pdf)) and were interpreted with the aid of molecular dynamics simulations.

The ^13^C chemical shift of the bryolog carbonyl label is upfield and partially resolved from the PKCδ-C1b and phospholipid carbonyl peaks, as evident in the C{F} REDOR S~0~ spectrum at 128 *T*~r~ (17.92 ms) ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C, bottom left spectrum). Thus, a direct spectral subtraction was performed for each REDOR measurement using spectra obtained identically from the \[^2^H~3~\]PDAc--PKCδ-C1b--phospholipid complex, lacking ^13^C enrichment ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C, top left spectrum). This yielded a REDOR S~0~^13^C spectrum wherein the only carbonyl contributions arose from the bryolog ^13^C label ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C, bottom right spectrum). C{F} REDOR spectra were obtained for six REDOR evolution times for the \[^19^F,^13^C,^2^H~3~\]bryolog--PKCδ-C1b--phospholipid complex and the \[^2^H~3~\]PDAc--PKCδ-C1b--phospholipid complex, requiring a total signal acquisition time of 42 and 45 days, respectively. The C{F} REDOR results yielded a dephasing curve that could only be attributed to a distribution of distances ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A, top panel, and [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.7b00475/suppl_file/oc7b00475_si_001.pdf)).

Long time scale (∼500 μs aggregate simulation time), unbiased molecular dynamics simulations of the PKCδ-C1b--phospholipid--bryolog complex^[@ref29]^ were employed to examine low-energy conformations and identify distances between the ^13^C-, ^2^H-, and ^19^F-labeled sites. For the ^13^C- and ^19^F-labeled sites, the low-energy conformations ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A, bottom panel) mapped to a minor distribution with the ^13^C--^19^F distances centered around 8 Å and a major distribution with the ^13^C--^19^F distances centered around 11 Å ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A, bottom panel). These ^13^C--^19^F distance distributions were used as guidance to fit the experimental REDOR data points. A good fit was obtained ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A, top panel, solid line) with distance distributions ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A, top panel, inset) very similar to those of the MD simulations ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A, bottom panel). The ultimate dephasing should reach a plateau of approximately 1.0, accounting for all the ^13^C--^19^F internuclear pairs. This was supported by a ^2^H Hahn echo spectrum, indicating that almost all bryolog 1 was PKCδ-C1b bound ([Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.7b00475/suppl_file/oc7b00475_si_001.pdf)). Thus, the REDOR NMR results confirmed the presence of the multiple low-energy conformers found by molecular dynamics, with a distribution of distances centered around two distances, a minor population (20%) at ∼8 Å and a major population (80%) at 11 Å ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A).

C{D} REDOR results were also indicative of long-range contacts ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). Molecular dynamics suggested that bryolog 1 bound to PKCδ-C1b would contain two major distributions of ^13^C--^2^H distances centered near 10 and 16 Å. Practically, a distance of 16 Å would be too far to measure experimentally with REDOR, with less than 1% theoretical dephasing even after a REDOR evolution time of 22.40 ms. Yet, the presence of such a conformation was supported by the REDOR data which matched the simulated dephasing expected for the presence of a distribution wherein 55% of the C--D distances are centered at the closer distance of 10 Å and 45% centered at the longer 16 Å distance ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B, top panel). The distribution of distances centered at 10 Å dominated the dephasing, as expected, wherein the C{D} REDOR ΔS/S~0~ plateau was expected to reach 41% (∼55% of the theoretical 74%), accounting for the observed population of shorter ^13^C--^2^H distances. The remaining 45% of the ^13^C--^2^H distances are too distant to be measured with REDOR and were predicted to be centered at 16 Å by the molecular dynamics simulations. These C{D} REDOR results required a total acquisition time of 53 days.

![Identification and quantification of distance distributions for PKCδ-C1b-bound bryolog 1 by REDOR NMR and molecular dynamics simulations. (A) C{F} REDOR, (B) C{D} REDOR, and (C) D{F} REDOR dephasing data with fits by distribution of distances (top panels) and corresponding distributions of the C--F, C--D, and D--F distances of bryolog 1 as a function of the free energy of the PKCδ-C1b--bryolog--phospholipid complex as calculated by molecular dynamics simulations.](oc-2017-00475g_0002){#fig3}

![Structures of the PKCδ-C1b-bound bryolog 1 and plausible PKCδ-C1b dimers by REDOR NMR and molecular dynamics simulations. (A) Two representative bryolog conformers from the molecular dynamics simulations. (B) D{F} REDOR spectra obtained for the evolution time of 13.44 ms reported in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C. Preferential dephasing of the spinning sidebands indicates orientational preferences for the ^2^H--^19^F internuclear vector. (C) An intermolecular arrangement of two PKC-bound bryolog complexes that maintains a short 5--7 Å ^2^H--^19^F intermolecular distance and reveals the presence of plausible protein--protein interactions in a possible dimeric complex.](oc-2017-00475g_0003){#fig4}

The molecular dynamics simulations predicted a narrow distribution of ^2^H--^19^F distances centered at 13 Å ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C, bottom panel). The simulated REDOR curve for this single distribution centered at 13 Å reached a maximum dephasing of only 2.4% after 22.40 ms. However, results from D{F} REDOR revealed the presence of strong dephasing at early evolution times, e.g., 6.5% dephasing after just 4.48 ms. Thus, there is a shorter than anticipated ^2^H--^19^F distance that dominated the observed dephasing. The dephasing (acquired with an acquisition time of 46 days) could be fit to a distribution in which 22% of ^2^H--^19^F distances are centered at 6 Å ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C, top panel). A 6 Å *intramolecular* proximity is not likely based on the molecular dynamics free energy calculations and the unfavorable ligand distortion that would be required. This suggests the presence of an *intermolecular* distance associated with an arrangement in which the ^2^H of one bryolog is proximate to the ^19^F of a neighboring bryolog. Furthermore, the individual spinning sidebands exhibited different levels of dephasing, indicating that the observed D{F} REDOR dephasing arose from a ^2^H--^19^F pair with orientational preferences ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B).

We examined whether such a short interligand ^2^H--^19^F distance was compatible with an arrangement in which two bryolog-bound PKCδ-C1b complexes are proximate. With only the restraint of a 5--7 Å ^2^H--^19^F intermolecular proximity, a pairing of two PKC peptides emerged with regions of complementarity between the two peptides, as illustrated in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C, specifically including interactions between H16 and K45 of peptide 1 and E44 of peptide 2, and interactions between D15 of peptide 1 and K26 and H40 of peptide 2. There are also no intermolecular ^13^C--^2^H or ^13^C--^19^F distances in the modeled dimer that would have been in the detection range of the REDOR measurements. Thus, the REDOR data are compatible with a model in which some bryolog--PKCδ-C1b complexes can dimerize through contacts consistent with specific protein--protein interactions. This represents a new type of protein--protein interaction for PKC and could potentially contribute to the multiple functions of PKC modulators.

Conclusions {#sec3}
===========

REDOR NMR and molecular dynamics simulations on the three-component PKCδ-C1b--ligand--phospholipid system independently support the presence of a distribution of PKC-bound bryolog conformations. In contrast to the bryolog, PDAc exhibits partitioning between a mobile lipid-associated state and a conformationally static PKCδ-C1b-bound state ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C and Figure S11 of ref ([@ref29])). We believe that these molecular differences ultimately contribute to their functional differences, wherein bryostatin is a promising candidate for various therapeutic indications and the phorbol esters are tumor promoters. The presence of a distribution of conformations for the bryolog could have contributed to previous failed efforts to obtain crystalline bryostatin--PKC complexes, and the relatively low resolution (4.0 Å) of the only full-length PKC crystal structure.^[@ref43]^ Molecular dynamics simulations of protein folding and macromolecular interactions have been transformative in generating *in silico* atomistic views of the possible pathways and conformational sampling involved in molecular recognition. Yet, drug design, biological assays, and drug development strategies are often based on single static structures such as the single-snapshot total structures obtained from X-ray crystallography. In contrast, REDOR NMR captured the conformational plasticity of the bryostatin--PKCδ-C1b--phospholipid system. These REDOR studies suggest that PKC modulators, and possibly other enzyme modulators (for example, Factor Xa bound ligands^[@ref56]^), exist in multiple bound states that contribute collectively to affinity but individually or collectively to function. This changes approaches to analogue design from a focus on static single-state structures to multistate dynamic systems accessible through long-range molecular dynamics simulations and REDOR experiments that integrate microenvironment contributions.

Flexibility in the ligand structure and binding could be important to the functional consequences of bryostatin binding and PKC function, in contrast to PDAc and phorbol esters as tumor promoters. Our work now provides a platform to evaluate the binding modes of other analogues and to establish possible correlations for the presence of ligand binding distributions with effects on PKC-associated function. We believe that the evaluation of selectivity and function of candidate PKC modulators, as well as the design of new modulators, should be addressed in terms of quantitative structure activity relationships using a dynamic multistate model, a recommendation also applicable to other membrane-associated proteins. Finally, the direct detection of a short ^2^H--^19^F distance was identified only through the REDOR dephasing, and we hypothesize that this could reflect the presence of PKC protein--protein interactions where two bryologs come into proximity, as illustrated in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C.

PKC and its C1 domain have many physiological states, and we have established fundamental atomic-level distances of biologically active ligands in the membrane-associated structure of the PKCδ-C1b domain. Biorelevant atomic-level detail for bryostatin, phorbol esters, and other PKC ligands is invaluable for the design of more PKC isoform selective ligands and therapeutic leads and, more generally, for understanding the functional role of PKC in the membrane microenvironment. By extending the reach of structural analysis from single-state static systems to multistate systems of higher order complexity, this work presents new opportunities to investigate how protein--ligand structures are influenced by membrane composition and type of bound modulator, and how these connect to function.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acscentsci.7b00475](http://pubs.acs.org/doi/abs/10.1021/acscentsci.7b00475).Materials and methods, Tables S1 and S2, and Figures S1--S5 ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.7b00475/suppl_file/oc7b00475_si_001.pdf))
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